Cellectis (CLLS) Cash & Equivalents Growth (1y) (2014 - 2026)
Cellectis (CLLS) Cash & Equivalents Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | -72.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.70% |
| Dec 31, 2025 | -57.05% |
| Sep 30, 2025 | -67.16% |
| Jun 30, 2025 | -59.87% |
| Mar 31, 2025 | 3.79% |
| Dec 31, 2024 | 4.79% |
| Sep 30, 2024 | 136.18% |
| Jun 30, 2024 | 76.62% |
| Mar 31, 2024 | 47.24% |
| Dec 31, 2023 | 46.66% |
| Sep 30, 2023 | -31.02% |
| Jun 30, 2023 | -34.81% |
| Mar 31, 2023 | -46.07% |
| Dec 31, 2022 | -49.79% |
| Sep 30, 2022 | -53.66% |
| Jun 30, 2022 | -47.85% |
| Mar 31, 2022 | -25.35% |
| Dec 31, 2021 | -23.02% |
| Sep 30, 2021 | -19.25% |
| Jun 30, 2021 | -4.79% |